These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 32331272)

  • 1. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.
    Hassell TJW; Charles D
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32331272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R; Cardoso F; Truong DD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin physiology in focal hand and cranial dystonia.
    Karp BI
    Toxins (Basel); 2012 Nov; 4(11):1404-14. PubMed ID: 23202323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
    Karp BI; Alter K
    Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of focal dystonias with botulinum neurotoxin.
    Hallett M; Benecke R; Blitzer A; Comella CL
    Toxicon; 2009 Oct; 54(5):628-33. PubMed ID: 19103214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Craniocervical dystonia: clinical and pathophysiological features.
    Colosimo C; Suppa A; Fabbrini G; Bologna M; Berardelli A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():15-21. PubMed ID: 20590803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials.
    Del Sorbo F; Albanese A
    Toxicon; 2015 Dec; 107(Pt A):89-97. PubMed ID: 26365917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience.
    Aquino CC; Felício AC; Castro PC; Oliveira RA; Silva SM; Borges V; Ferraz HB
    Arq Neuropsiquiatr; 2012 Sep; 70(9):662-6. PubMed ID: 22990720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oromandibular dystonia.
    Lee KH
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Oct; 104(4):491-6. PubMed ID: 17689275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Botulinum Toxin for Treatment of the Dystonias.
    Berardelli A; Conte A
    Handb Exp Pharmacol; 2021; 263():107-126. PubMed ID: 31820178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is new in the era of focal dystonia treatment? Botulinum injections and more.
    Cetinkaya A; Brannan PA
    Curr Opin Ophthalmol; 2007 Sep; 18(5):424-9. PubMed ID: 17700237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of dystonias including Meige's syndrome.
    Behari M
    Neurol India; 2018; 66(1):36-37. PubMed ID: 29322952
    [No Abstract]   [Full Text] [Related]  

  • 17. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dystonia, botulinum neurotoxin, and the aviator.
    Feinberg MJ
    Aviat Space Environ Med; 1999 Dec; 70(12):1235-7. PubMed ID: 10596783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.
    Dadgardoust PD; Rosales RL; Asuncion RM; Dressler D
    J Neural Transm (Vienna); 2019 Feb; 126(2):141-148. PubMed ID: 30604200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Focal or Segmental Dystonia Resistant to Botulinum Toxin: How Do You Treat Patients in Whom Botulinum Toxin Treatment Has No Effect?].
    Nomura T
    Brain Nerve; 2022 May; 74(5):581-587. PubMed ID: 35589651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.